Neural Plasticity in the Ventral Tegmental Area, Aversive Motivation during Drug Withdrawal and Hallucinogenic Therapy

Introduction

Aversive motivation — the tendency to avoid or escape potentially harmful or punishing stimuli — has been implicated as a central driver of substance use when individuals seek negative reinforcement. The text positions this view against the older monoamine deficit model of mood disorders and highlights a complementary theory: maladaptive changes in neural plasticity, including neurogenesis, synaptic remodelling and receptor expression, underlie exaggerated aversive motivation. Brain-derived neurotrophic factor (BDNF) is presented as a key regulator of such plasticity; while reduced BDNF in hippocampus and prefrontal cortex has been associated with depressive states, increased BDNF in the mesolimbic system appears linked to heightened aversive motivation and addiction-related plasticity. This dichotomy suggests that non-specific increases of BDNF may be therapeutically counterproductive and that treatments with regionally selective effects on plasticity are required. Vargas-Perez and colleagues set out to describe the neurobiological framework that connects BDNF-dependent plasticity in the ventral tegmental area (VTA) with aversive motivation during drug withdrawal, and to summarise evidence that classical hallucinogens (5-HT2A agonists) can reverse or prevent this maladaptive plasticity. The paper concentrates on mechanisms by which chronic drug exposure or stress elevates BDNF in the VTA, how this alters GABA-A signalling and the balance between dopaminergic and non-dopaminergic reward circuits, and how single administrations of 5-HT2A agonists such as psilacetin/psilocybin may selectively normalise VTA plasticity while enhancing cortical and hippocampal plasticity relevant to therapeutic effects. The review primarily integrates preclinical evidence and places psychedelic action within a learning/plasticity framework for treating mood-related disorders and addiction.